A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors GSK
- 06 Jun 2012 Results were reported in Headache.
- 23 Feb 2010 Actual number of patients (173), actual end date (Dec 2007) as reported by ClinicalTrials.gov.
- 20 Aug 2008 Status changed from recruiting to completed, as reported on ClinicalTrials.gov.